Stevanato Group SpA (STVN) Stock AnalysisSTVNStevanato Group SpA

Stevanato Group SpA is an Italy-based manufacturer and distributor engaged in two segments: Biopharmaceutical and Diagnostic Solutions and Engineering, including the production and distribution of drug containment solutions, drug delivery systems, and diagnostic solutions in the pharmaceutical industry. The Company delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The Company operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States. It operates in the Healthcare sector (SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS industry).

Stevanato Group (STVN) is currently trading at $19.40, which is below the average analyst price target of $22 to $25, suggesting potential upside. However, the RSI is at a low 25.664, indicating that the stock may be oversold. The company has shown a gross margin of 28.7% in Q2 2026, reflecting effective cost management. The main risk is the recent 1-year price change of -16.77%, indicating a significant decline in stock performance over the past year, which could deter new investors.